Trial Profile
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs SRP-5051 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 19 Nov 2021 Status changed from active, no longer recruiting to discontinued.
- 03 May 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2020 Planned number of patients changed from 54 to 60.